• Prophylactics of obstetric disorders in anemia of chronic disease
To content Full text of article

Prophylactics of obstetric disorders in anemia of chronic disease

PERINATOLOGIYA I PEDIATRIYA. 2017.2(70):37-41; doi 10.15574/PP.2017.70.37

Davydova Iu. V., Ogorodnyk A. A., Limancka A. Yu., Bayder A. K., Butenko L. P.
SI «Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine», Kyiv

The article presents data of the pathogenesis, clinical peculiarities and treatment of anemia of chronic disease observed in inflammatory, infectious and oncological diseases. The main biomarkers, diagnostic tools, and risks of anemia of chronic disease in pregnant women with chronic diseases are analyzed in the article. Anemia of chronic disease makes a significant contribution to increasing incidence of obstetric disorders in pregnants with inflammatory, autoimmune, infectious, malignant diseases. The pathogenesis of anemia of chronic disease, with the key role of hepcidin in the regulation of iron absorption and release is presented. Proper analysis of inflammation and anemia biomarkers allows developing the efficacious therapeutic approach to anemia of chronic disease in pregnant women. The intravenous iron therapy in this group of pregnant women is appropriate and allows to achieve the rapid effect in the treatment of anemia with a high safety profile.

Key words: anemia of chronic inflammation, autoimmune diseases, pregnancy, hepcidin, biomarkers of anemia, intravenous iron.

1. Adamson JW. (2008).The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program: 159—165. https://doi.org/10.1182/asheducation-2008.1.159; PMid:19074075

2. Bencaiova G, von Mandach U, Zimmermann R. (2009). Iron prophylaxis in pregnancy: Intravenous route versus oral route. Eur J Obstet Gynecol Reprod Biol. 144: 135—139. https://doi.org/10.1016/j.ejogrb.2009.03.006; PMid:19406557

3. Breymann C. (2006). The use of iron sucrose complex for anemia in pregnancy and the postpartum period. Semin Hematol. 43: S28—S31. https://doi.org/10.1053/j.seminhematol.2006.08.002

4. Chandler G, Harchowal J, Macdougall IC. (2001). Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis. 38: 988—991. https://doi.org/10.1053/ajkd.2001.28587; PMid:11684551

5. Cavill I, Auerbach M, Bailie GR et al. (2006). Iron and the anaemia of chronic disease: A review and strategic recommendations. Curr Med Res Opin. 22: 731—737. https://doi.org/10.1185/030079906X100096; PMid:16684434

6. Bayoumeu F, Subiran-Buisset C, Baka NE et al. (2002). Iron therapy in iron deficiency anemia in pregnancy: Intravenous route versus oral route. Am J Obstet Gynecol. 186: 518—522. https://doi.org/10.1067/mob.2002.121894; PMid:11904617

7. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. (2004).On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 19: 1571—1575. https://doi.org/10.1093/ndt/gfh185; PMid:15150356

Содержание журнала Full text of article